These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17551677)

  • 1. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.
    Bencardino K; Manzoni M; Delfanti S; Riccardi A; Danova M; Corazza GR
    Intern Emerg Med; 2007 Mar; 2(1):3-12. PubMed ID: 17551677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibitors: what have we learned from the treatment of lung cancer?
    Giaccone G; Rodriguez JA
    Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
    Amler LC; Goddard AD; Hillan KJ
    Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predicting response to EGFR tyrosine kinase inhibitors.
    Engelman JA; Jänne PA
    Semin Respir Crit Care Med; 2005 Jun; 26(3):314-22. PubMed ID: 16052433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
    Riely GJ
    Lung Cancer; 2008 Jun; 60 Suppl 2():S19-22. PubMed ID: 18513580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    Pao W; Miller VA
    J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.
    Edelman MJ
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S3-8. PubMed ID: 16459173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
    Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
    Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
    Haber DA; Bell DW; Sordella R; Kwak EL; Godin-Heymann N; Sharma SV; Lynch TJ; Settleman J
    Cold Spring Harb Symp Quant Biol; 2005; 70():419-26. PubMed ID: 16869779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
    Rosell R; Taron M; Reguart N; Isla D; Moran T
    Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.